CB2 Insights announced its FY2018 financial results after a transformative year. A Merida portfolio company, CB2 focuses on predictive data analytics to bring real-world evidence driven from the point-of-care to the medical cannabis community.
Highlights included total revenue of C$10.8 million up from $280 thousand the year prior, gross profit of C$7.9 million and adjusted EBITDA loss of $1.1 million. CB2 just listed publicly and is a stock worth watching as they are a core articulation of Merida's thesis that medical data will be a crucial element helping medical cannabis shift into cannabis-based medicine.
Click here for the full release.